期刊文献+

可溶性ST-2和Galectin-3水平与肥厚型心肌病患者室间隔心肌切除术后心房颤动的相关性分析 被引量:1

Association of soluble ST-2 and galectin-3 with new onset atrial fibrillation after ventricular septal myectomy in patients with hypertrophic cardiomyopathy
原文传递
导出
摘要 目的探讨可溶性ST-2和半乳糖凝集素-3(Galectin-3)水平与肥厚型心肌病患者行室间隔心肌切除术后心房颤动(房颤)的相关性。方法纳入2011年3月至2016年2月在阜外医院成人外科58病区行室间隔心肌切除术的肥厚型心肌病患者170例,收集患者临床资料。采用酶联免疫吸附法检测可溶性ST-2与Galectin-3浓度,分析术后房颤发生的相关因素。结果共16例于住院期间发生术后房颤。与无术后房颤患者相比,发生术后房颤的患者平均年龄更大[(49.8±9.6)岁对(42.1±14.2)岁,P=0.036],吸烟患者比例更高(62.5%对38.3%,P=0.047)。两组患者之间可溶性ST-2[9.0(7.3~22.2)对12.6(8.7~18.0)ng/ml,P=0.37]和Galectin-3[7.2(6.2~9.9)对7.1(5.4~8.7)ng/ml,P=0.45]浓度差异无统计学意义。经多因素回归分析,年龄是术后房颤发生的独立危险因素[OR=1.065(95% CI 1.007~1.126),P=0.028]。结论可溶性ST-2和Galectin-3与肥厚型心肌病患者室间隔心肌切除术后房颤发生无相关。年龄增长可能是术后房颤发生的独立危险因素。 ObjectiveWe aimed to explore the association between soluble ST-2 and galectin-3 (Gal-3) levels and new onset atrial fibrillation after ventricular septal myectomy in patients with hypertrophic cardiomyopathy (HCM) .MethodsOne hundred seventy consecutive HCM patients who underwent ventricular septal myectomy in Fuwai Hospital from March 2011 to February 2016 were enrolled. Demographics, clinical characteristics and echocardiographic parameters of these patients were collected. Soluble ST-2 and Gal-3 levels were examined by Enzyme-linked immunosorbent assay (ELISA) . The association of these parameters with new onset postoperative atrial fibrillation (POAF) were assessed.ResultsPOAF was documented in 16 patients in hospital. POAF patients were older[ (49.8±9.6) years vs. (42.1±14.2) years, P=0.036]and had more smoking (62.5% vs. 38.3%, P=0.047) . Soluble ST-2 [9.0 (7.3-22.2) ng/ml vs. 12.6 (8.7-18.0) ng/ml, P=0.37]and Gal-3[7.2 (6.2-9.9) ng/ml vs. 7.1 (5.4-8.7) ng/ml, P=0.45]in patients with POAF were similar to that in those without POAF. In multivariable regression analysis, age (odds ratio 1.065, 95% CI 1.007-1.126, P=0.028) was an independent predictor of POAF.ConclusionPlasma soluble ST-2 and Gal-3 levels were not associated with the occurrence of POAF in patient with HCM who underwent ventricular septal myectomy. Advanced age might be an independent predictor of POAF in HCM patients after surgical ventricular septal myectomy.
作者 鲁洁 黄晓红 伍熙 郭颖 宋昌鹏 郑欣馨 房晓楠 王水云 Lu Jie;Huang Xiaohong;Wu Xi;Guo Ying;Song Changpeng;Zheng Xinxin;Fang Xiaonan;Wang Shuiyun(Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China)
出处 《中华心律失常学杂志》 2018年第5期424-428,共5页 Chinese Journal of Cardiac Arrhythmias
基金 国家自然科学基金(81570276)
关键词 心房颤动 可溶性ST-2 半乳糖凝集素-3 Atrial fibrillation Soluble ST-2 Galectin-3
  • 相关文献

参考文献2

二级参考文献15

  • 1Maron BJ,Olivotto I, Bellone P,et al.Clinical profile of stroke in900 patients with hypertrophic cardiomyopathy.J Am Coll Cardiol,2002,39:301-307.
  • 2Olivotto I,Cecchi F,Casey SA,et al.Impact of atrial fibrillation onthe clinical course of hypertrophic cardiomyopathy. Circulation,2001,104:2517-2524.
  • 3Liu X,Ouyang F,Mavrakis H,et al.Complete pulmonary vein isola-tion guided by threedimensional electroanatomical mapping for thetreatment of paroxysmal atrial fibrillation in patients with hyper-trophic obstructive cardiomyopathy.Europace,2005 J\A2\-427.
  • 4Kilicaslan F,Verma A,Saad E,et al.Efficacy of catheter ablation ofatrial ftbrillation in patients with hypertrophic obstructive cardiomy-opathy. Heart Rhythm, 2006,3 : 275-280.
  • 5Derejko P,Polaiiska M,Chojno抑ka L,et al.Catheter ablation of atrialfibrillation in patients with hypertrophic cardiomyopathy : atrial fibrilla-tion type determines the success rate.Kardiol Pol,2013,71 : 17- 24.
  • 6Gaita F,Di Donna P,Olivotto I,et al.Usefulness and safety of traxi-scatheter ablation of atrial fibrillation in patients with liypertrophiccardiomyopathy.Am J Cardiol,2007,99; 1575-1581.
  • 7Bunch TJ,Munger TM,Friedman PA,et al.Substrate and procedur-al predictors of outcomes after catheter ablation for atrial fibrillationin patients with hypertrophic cardiomyopathy. J Cardiovasc Electro-physiol, 2008 ,19:1009-1014.
  • 8Di Donna P,Olivotto I,Delcre SD,et al.Efficacy of catheter abla-tion for atrial fibrillation in hypertrophic cardiomyopathy: impact ofage,atrial remodeling,and disease progression.Europace,2010,12:347-355.
  • 9Gersh BJ,Maron BJ,Bonow RO,et al.2011 ACCF/AHA guidelinesfor the diagnosis and treatment of hypertrophic cardiomyopathy. JThorac Cardiovasc Surg.2011,142:el53-203.
  • 10Wang YL,Liu X,Tan HW,et al.Evaluation of lines lesions in theleft and right atrium in ablation of longstanding atrial fibrillation.Pacing Clin Electrophysiol, 2013 May 16.

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部